PREVAIL trial and interim analysisPREVAIL is evaluating obicetrapib in approximately 10,000 patients with established atherosclerotic cardiovascular disease. In an on-treatment analysis from the BROADWAY and BROOKLYN studies, Kastelein said obicetrapib reduced LDL cholesterol by 43.5% at week four and 41.1% at week 12. The company’s fixed-dose combination of obicetrapib and ezetimibe reduced LDL cholesterol by 63% at week four and 61% at week 12, according to the presentation. It includes obicetrapib, the fixed-dose combination and placebo groups, and is evaluating LDL cholesterol, small dense LDL particles and lipoprotein(a). It includes obicetrapib, the fixed-dose combination and placebo groups, and is evaluating LDL cholesterol, small dense LDL particles and lipoprotein(a).